Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 19/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604650 | 0.83 | HRH4 (1.00) | HRH4HRH1HRH3 | |
| SCHEMBL6130883 | 0.79 | HRH4 (1.00) | HRH4HRH1HRH3 | |
| SCHEMBL12501380 | 0.77 | APEX1 (0.51) | HRH4 | |
| SCHEMBL605903 | 0.77 | HRH4 (1.00) | HRH4 | |
| SCHEMBL604398 | 0.75 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL12501410 | 0.75 | KMT2A (0.46) | HRH4L3MBTL1 | |
| SCHEMBL6130894 | 0.74 | HRH4 (1.00) | HRH4HRH1HRH3 | |
| SCHEMBL30309424 | 0.73 | HRH4 (0.59) | HRH4L3MBTL1 | |
| SCHEMBL12501493 | 0.72 | CDK1 (0.49) | L3MBTL1HRH3 | |
| Dimethylformamide SCHEMBL28004372 | 0.72 | APEX1 (0.44) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838895-B1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9096579-B2 | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2838895-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156608-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | INMT, IDO1, CHRM1 | HRH4 20/4885L3MBTL1 2568/4885HRH1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.